2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-158024
    NDT-19795 2272917-12-9
    NDT-19795 is an effective inhibitor of the NLRP3 inflammasome with an IC50 value of 66 nM in the PBMC method and 4.7 μM in the WB method. NDT-19795 is a carboxylic acid-active substance that can be converted from NT-0796 (HY-156438) within cells. NDT-19795 can be used for the study of neurological diseases.
    NDT-19795
  • HY-16579A
    Etifoxine 21715-46-8 99.96%
    Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents.
    Etifoxine
  • HY-17417A
    Naloxone 465-65-6 99.71%
    Naloxone is an antagonist of Opioid receptor. Naloxone alleviates opioid-overdose-induced respiratory depression. Naloxone may cause pulmonary edema and cardiac arrhythmias.
    Naloxone
  • HY-B0410A
    Pramipexole dihydrochloride hydrate 191217-81-9 ≥98.0%
    Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
    Pramipexole dihydrochloride hydrate
  • HY-B0524A
    Betahistine dihydrochloride 5579-84-0 99.82%
    Betahistine dihydrochloride is an orally active histamine H1 receptor agonist and a H3 receptor antagonist. Betahistine dihydrochloride is used for the study of rheumatoid arthritis (RA).
    Betahistine dihydrochloride
  • HY-B0884A
    Minaprine dihydrochloride 25953-17-7 99.90%
    Minaprine dihydrochloride is a reversible inhibitor of MAO-A; weakly inhibit acetylcholinesterase; an antidepressant for treatment of depression.
    Minaprine dihydrochloride
  • HY-B1052A
    Lofexidine 31036-80-3 99.08%
    Lofexidine is a selective α2-receptor agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal.
    Lofexidine
  • HY-B1626A
    Demecarium Bromide 56-94-0
    Demecarium Bromide (BC-48) is a potent cholinesterase inhibitor, with an apparent affinity (Kiapp) of 0.15 μM. Demecarium Bromide (BC-48) is used as a glaucoma agent.
    Demecarium Bromide
  • HY-B1657A
    Fosphenytoin disodium 92134-98-0 99.81%
    Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
    Fosphenytoin disodium
  • HY-B1836A
    Meldonium dihydrate 86426-17-7 ≥99.0%
    Meldonium (MET-88) dihydrate functions as a cardioprotective agent by cpmpetetively inhibiting γ-butyrobetaine hydroxylase (BBOX) and carnitine/organic cation transporter type 2 (OCTN2). Mildronate dihydrate exhibits IC50 values of 34-62 μM for human recombinant BBOX and an EC50 of 21 μM for human OCTN2. Meldonium dihydrate is a fatty acid oxidation inhibitor.
    Meldonium dihydrate
  • HY-P0176A
    PACAP (1-27), human, ovine, rat TFA 99.87%
    PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC50s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively.
    PACAP (1-27), human, ovine, rat TFA
  • HY-P0197A
    Neurokinin A TFA 2828433-19-6 99.57%
    Neurokinin A TFA (Substance K TFA), a peptide neurotransmitter of the tachykinin family, acts via the NK-2 receptor. Neurokinin A acts as a major mediator in human airway and gastrointestinal tissues.
    Neurokinin A TFA
  • HY-P0214A
    Autocamtide-2-related inhibitory peptide TFA 99.20%
    Autocamtide-2-related inhibitory peptide (TFA) is a highly specific and potent inhibitor of CaMKII with an IC50 of 40 nM.
    Autocamtide-2-related inhibitory peptide TFA
  • HY-P0256A
    Apamin TFA 98.35%
    Apamin TFA (Apamine TFA) is an 18 amino acid peptide neurotoxin found in apitoxin (bee venom), is known as a specifically selective blocker of Ca2+-activated K+ (SK) channels and exhibits anti-inflammatory and anti-fibrotic activity.
    Apamin TFA
  • HY-P1237A
    C-Type Natriuretic Peptide (CNP) (1-22), human TFA 1966153-17-2 98.10%
    C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor.
    C-Type Natriuretic Peptide (CNP) (1-22), human TFA
  • HY-P1594A
    Dynorphin A (1-10) (TFA)
    Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) (TFA) also blocks NMDA-activated current with an IC50 of 42.0 μM.
    Dynorphin A (1-10) (TFA)
  • HY-P1675A
    Acetyl-PHF6 amide TFA
    Acetyl-PHF6 amide TFA (AcPHF6 TFA) is a tau derived hexapeptide.
    Acetyl-PHF6 amide TFA
  • HY-P1754A
    Tetanus toxin (830-843) TFA
    Tetanus toxin (830-843) TFA is a powerful neurotoxin that reaches by retroaxonal transport and transcytosis the cytoplasm ofspinal inhibitory intemeurons and blocks their ability to release neurotransmitters.
    Tetanus toxin (830-843) TFA
  • HY-U00050
    (E)-10-Hydroxynortriptyline 47132-16-1 99.66%
    (E)-10-Hydroxynortriptyline (E-10-OH-NT) is a metabolite of Nortriptyline (HY-B1417). Nortriptyline is a tricyclic antidepressant and the main active metabolite of Amitriptyline (HY-B0527A). E-10-OH-NT is about 50% as potent as nortriptyline as an inhibitor of the neuronal uptake of norepinephrine in vitro and exhibits less anticholinergic effects in man.
    (E)-10-Hydroxynortriptyline
  • HY-U00431
    CCG 203769 410074-60-1 99.76%
    CCG 203769 is a selective G protein signaling (RGS4) inhibitor, which blocks the RGS4-Gαo protein-protein interaction in vitro with an IC50 of 17 nM.
    CCG 203769
Cat. No. Product Name / Synonyms Application Reactivity